Joshua Greally

Joshua Greally is a Business Development Associate at Peak Proteins since May 2023. Prior to this role, Joshua served as a Senior Scientist at BiVictriX Therapeutics plc from January 2021 to May 2023, focusing on bioconjugation. Joshua completed a PhD at The University of Manchester, conducting research on chemokine-inhibitor conjugates for blood cancer treatment from September 2017 to December 2020. Earlier experience includes working as an Associate Chemist at Redx Pharma, where Joshua designed and synthesized small molecule inhibitors from October 2015 to September 2017. Educational background includes an MSc in Drug Discovery from the University of Surrey and a BSc in Chemistry from the University of Liverpool, complemented by A-level studies in sciences at SFX College.